Loading...

About Carolina BioOncology Institute

Carolina BioOncology Institute is reimagining access to groundbreaking cancer treatments, a disruptive approach to bench-to-bedside medicine. Our unique business model leverages curated access to Phase I Clinical Trials with on site research and clinical laboratory support for the treatment of human disease.

Patient & Sponsor Services

Clinical Trials

Patients participating in a clinical trial have the opportunity to receive new research treatments before they are widely available. With Phase I clinical trial capabilities at our facility in Huntersville, NC, we’re able to quickly enroll patients in the newest trials and provide the highest quality of patient care in a community-based setting.

Learn More

CLIA Laboratory Services

Our on site Clinical Laboratory can provide routine patient sample analyses including hematology, urinalysis, metabolic testing, and other diagnostic services. The facility is also high-complexity certified in Immunology and can perform CELLSEARCH CTC enumeration and COVID-19 screening as requested or provider-ordered.

Learn More

Contract Research

Human Applications Lab (HAL) staff perform translational Tumor Immunology research for internal projects and biopharmaceutical sponsors. Expert staff are trained in GDP, GLP, and cGMP regulations in order to provide services like cell processing, technology transfer, process scale-up, and other IND-enabling solutions.

Learn More

In The News

BioCytics and CBOI Publish Novel Solution for Immune Cell Therapy Manufactured at the Point-of-Care

Transfusion – 10/9/26

The team at BioCytics and Carolina BioOncology Institute (CBOI) collaborated to produce an article recently published in a special supplemental edition of Transfusion, the official journal of the American Association of Blood and BioTherapeutics. The Transfusion special edition is called “Evolving Biotherapies: Stakeholders, Solutions, and the Science of Tomorrow”. BioCytics-CBOI’s manuscript is titled “Enabling community-based autologous adaptive immune cellular therapy manufactured at the point of care: A narrative review of global regulatory frameworks, affordability, and implementation strategy of a novel integrated facility and digital platform in the United States”.  

Full Press Release

Carolina BioOncology Institute is Now Accredited with the Better Business Bureau

Better Business Bureau – 10/6/26

Carolina BioOncology Institute is pleased to announce they have recently become accredited with the Better Business Bureau (BBB) of Southern Piedmont and Western North Carolina with an A+ rating.  Accreditation with the BBB indicates a business that has been vetted according to their Eight Standards for Trust: safeguarding privacy, being responsive, building trust, advertising honestly, telling the truth, being transparent, honoring promises, and embodying integrity.  CBOI has always strived to provide the best patient care in a highly ethical manner and this accreditation is a welcome validation of these efforts.
BBB Profile

Strategic Collaboration to Develop Advanced Cancer Screening Platforms and Companion Diagnostics

BioCytics and LIDE Biotech Initiate Pilot Project to Develop PDX Cancer Models – 8/13/26

BioCytics, Inc., and LIDE Biotech are proud to announce the formation of a strategic alliance to develop advanced screening platforms and companion diagnostics for immune-based cancer cell therapies. This collaboration combines BioCytics’ specialized cell manufacturing capabilities with LIDE’s unique, patient-derived xenograft technologies (PDX, miniPDX®, and IO-based PDX models) to streamline the development of immuno-oncology (IO) treatments.

Full Press Release

Unlocking the Dark Genome of Cancer: A Landmark Collaboration Between BioCytics and UNC Charlotte

Collaboration with UNC Charlotte – 7/20/26

BioCytics and UNC Charlotte, along with Carolina BioOncology Institute, are embarking on a new project to study as-yet unidentified sequences in the human genome that might be responsible for cancer cell growth and treatment response.  BioCytics’ Chief Scientific Officer, Dr. Renaud Warin, and UNC Charlotte Associate Professor, Dr. Richard White III, are embarking on a collaboration that involves studying the “dark genome” of cancer cells.  The dark genome is the portion of the genome (approximately 98%) that does not directly code for a protein.  The goal of this project is to identify viral and immune sequences involved in the progression of cancer and immune response to cancer.

Full Press Release
See All News

View Our Facilities